MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Triple Helix Framework
Industry
Architects: Small & Medium Size Business (SMBs), Product Development, De-Risking, Validation, Building Niche & Emerging Markets
*Architects: Infectious Disease _ AntiFungal
Cidara Therapeutics, Inc. (NASDAQ: CDTX)*
Organization & Developments: Cidara
org novartis
Parents
Cidara Therapeutics, Inc. (NASDAQ: CDTX)*
Children
* Cidara’s lead DFC candidate, CD388, is a long-acting antiviral designed to achieve universal prevention of seasonal and pandemic influenza with a single dose by directly inhibiting viral proliferation.
*Antifungal candidate rezafungin acetate
*Cidara is a clinical stage biotechnology company developing novel anti-infectives to address serious infections.
*Cidara Therapeutics is using its proprietary Cloudbreak® platform to develop novel drug-Fc conjugates (DFCs) comprising targeted small molecules or peptides coupled to a proprietary human antibody fragment (Fc).
2017: ROTY Edition 1 Volume 56: Cidara Therapeutics In The Spotlight
2021: Checking Back In On Cidara Therapeutics
2022: Cidara Therapeutics (CDTX) Investor Presentation - Slideshow_seekingalpha.com
2022: Cidara Therapeutics Could Soar On Rezafungin Approval_ seekingalpha.com
2023: Buy Cidara Therapeutics For Data Readout And European Foothold (NASDAQ:CDTX)
2023: Cidara Therapeutics: Promising Developments And A Speculative 'Buy' Recommendation (Rating Upgrade)_ seekingalpha.com
2024: Cidara axes 30% of staff to focus on flu prevention drug
2024: Cidara: Potential To Change Flu Prophylaxis Landscape With CD388
2025: Bullish On Cidara Therapeutics As It Doubles Down On CD388 For Universal Flu Prevention
2025: Cidara more than doubles on phase 2 flu preventative data
2025: Cidara Therapeutics: All Stars Aligning In Favor Of CD388
Jumps
*Key People: Cidara
Finance & Acquisition: Cidara